🎙️ Live now! Prof. Eui-Cheol Shin (KAIST, Korea) is presenting “Cytokine-induced bystander CD8+ T cell activation and its regulation in viral hepatitis” – part of our Translational Seminar Series.
Join the discussion live 👉 msteams.link/DGTP
#HepatitisD #D-SOLVE #HaDEA #EUHealth

🔴 Tune in now: Dr. Sabela Lens (Hospital Clínic de Barcelona) is sharing insights on “Understanding Hepatitis B/Delta: ongoing efforts” – part of our translational seminar series.
Join 👉 msteams.link/DGTP
#Hepatitis #D-SOLVE #HaDEA #EUHealth @ec.europa.eu

🧬 D-SOLVE lecture via MS Teams:
Hepatitis D in Mongolia – Screening Study among Mongol Migrants in Sweden
👤 Speakers from Karolinska/Sweden & Mongolia
🗓️ Tue, 23 Sept | 🕐 12:45–13:30 CET
🔗 bit.ly/46oxjnH
🔑 ID: 368 532 223 585 | PW: dq64Nb9t
#DSOLVE #HepatitisD #PublicHealth

🧬 Join the HBV Community Forum & Int. HBV Meeting in Berlin (Sept 8–12), on-site or online!
🎤 Science meets community – Hepatitis B & D!
D-SOLVE’s Heiner Wedemeyer & Helenie Kefalakes will be there.
👉 www.hbvmeeting.org
#HBVForum2025 #HepatitisB #HepatitisD

📢 EASL Congress: E. Degasperi from our #D-SOLVE Consortium presents results from a large real-life cohort on clinical outcomes of chronic hepatitis D patients. Rates of cirrhosis & liver-related events were lower than expected. ALT, age & HDV RNA were key determinants. #EASL2025 #HepatitisResearch

Researchers from Hannover Medical School (MHH) identified a marker on NK cells showing how Bulevirtid alleviates liver inflammation in Hepatitis D. Bulevirtid blocks viral entry and reduces inflammation, even with high viral load, by activating the immune marker TIGIT. More info: bit.ly/40VPqi3.

Welcome to the official Bluesky channel of the D‑SOLVE Consortium. We look forward to engaging with the scientific community and stakeholders committed to improving liver health worldwide. Stay tuned for updates and also check our website (www.d-solve-consortium.eu) for more information.